Bio + Health

Our Top 10 Bio Posts of 2019

a16z editorial Posted December 27, 2019

Biology is Eating the World: A Manifesto.

Biology today is where information technology was 50 years ago: Our ability to engineer biology will change how we diagnose, treat, manage disease; create new medicines and therapeutics; and change how we access, pay for, deliver healthcare. In short, biology is eating our world, and this is our manifesto.

So You Wanna Build a Software Company in Healthcare?

Building a software company in healthcare is hard, damn hard. In this conversation, a16z bio general partners share their mistakes and hard-earned lessons learned.

Software Has Eaten the World… and Healthcare is Next

Marc Andreessen first made the claim that software would eat the world back in 2011. In this episode we take a look back at that thesis, and on how software has (and hasn’t) delivered on that promise — especially in healthcare.

What’s in the Water at the George Church Lab?

Renowned geneticist George Church shares where we really are today with CRISPR to what it really takes to go from science fiction, to lab, to reality.

The Science and Business of Innovative Medicines

On average, only 1 out of 20 medicines works when we actually bring them into the human body. It’s incredible that we find any human medicine that works at all, given that human beings are the product of billions of years of evolution. So how does the world’s largest producer of medicines balance the science and the business of innovation? There’s lessons in here for big companies and startups alike.

The Economics of Expensive Medicines

This year we saw the most expensive medicine in history hit the market: a gene therapy for $2.1m. In this episode, an MIT economist shares how to think about the value and prices medicines of this new category of medicines pouring into our healthcare system.

Software Eats Care Delivery

It’s never been a better time to be a tech-based startup in the healthcare delivery space. We’re finally seeing the laying down of core infrastructure plus new business models and access points creating huge zones of opportunity. What are the key industry tailwinds leading to this perfect storm (aka, what’s different this time); what are some of those new approaches; and finally, what are the characteristics of a winning formula for startups here?

The Next Bio Startup: Born in the Wild vs Bred in Captivity

There’s a new founder in town, a new model of company building, and a whole new generation of bio companies coming. What are the tradeoffs between the old models and new?

What is a Medicine?

Just as the practice of medicine has evolved, the very concept of what a medicine is has as well.

A Guide to Making Data-Based Decisions in Health, Parenting, and Life

Are chia seeds actually that good for you? Will Vitamin E keep you healthy? Will breastfeeding babies make them smarter? What lies beneath all those studies… and how can we make smarter decisions based on them (or not)? (Bonus: the actual answers to all those questions and more.)

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.